TY - JOUR T1 - Predictive Value of Lesions for Relapses in Relapsing-remitting Multiple Sclerosis JF - American Journal of Neuroradiology JO - Am. J. Neuroradiol. SP - 284 LP - 291 VL - 22 IS - 2 AU - James A. Koziol AU - Simone Wagner AU - David F. Sobel AU - Lloyd S. Slivka AU - John S. Romine AU - Jack C. Sipe AU - Hans-Peter Adams Y1 - 2001/02/01 UR - http://www.ajnr.org/content/22/2/284.abstract N2 - BACKGROUND AND PURPOSE: Recent studies have suggested that enhancing lesions on contrast-enhanced T1-weighted MR images are predictive of impending exacerbations in cases of relapsing-remitting multiple sclerosis. We examined whether enhancing lesions, new enhancing lesions, and new hypointense lesions (“black holes”) could accurately predict exacerbations in a cohort of 50 patients with relapsing-remitting multiple sclerosis within a time frame of up to 6 months.METHODS: Data were obtained from 50 patients with relapsing-remitting disease. All patients underwent monthly MR imaging and clinical examinations for a period of 12 months. Putative predictors of clinical relapse were defined from enhancing lesions, new enhancing lesions, and new black hole outcomes, and their operating characteristics were studied.RESULTS: Overall, the positive predictive values (PV+) of enhancing lesions, new enhancing lesions, or new black holes for an exacerbation did not exceed 0.25 and the negative predictive values (PV−) were all near 0.9. The best predictor for new enhancing lesions was the occurrence of new enhancing lesions in each of the previous 3 months (PV+: 0.79 [95% confidence interval, 0.651–0.900]; PV−: 0.83 [95% confidence interval, 0.751–0.887]). Similarly, new black holes were predicted best by the occurrence of new black holes in each of the previous 2 months (PV+: 0.54 [95% confidence interval: 0.372–0.697]; PV−: 0.85 [95% confidence interval, 0.790–0.896]).CONCLUSION: None of the MR markers could predict an impending relapse with any reasonable degree of precision. Rather, the absence of MR markers is associated with a more favorable clinical course (ie, fewer relapses). ER -